New Delhi: Bharat Biotech International Limited announced on Friday that the company has signed an agreement with Brazil to supply 20 million doses of its covid-19 COVAXIN vaccine.
“The company has signed an agreement for the delivery of COVAXIN®️ during Q2 and 3Q 2021. The company is happy to collaborate with Brazil in its battle against Covid-19 and help its immunization program against the virus, “Bharat Biotech said in a statement.
There is great interest in COVAXIN®️ from many countries around the world, and the company is fully committed to guaranteeing supplies quickly and efficiently.
Krishna Ella, president and CEO of Bharat Biotech, recently said the Hyderabad-based vaccine maker will commission its third facility later this week and after that it will be able to produce at least 40 million doses. of vaccine every month. He said an increase in vaccine production could help reduce shortages globally.
Earlier this month, Bharat Biotech also announced the signing of a pact with Ocugen Inc., which will allow the U.S.-based biopharmaceutical firm to develop, supply and market the Covid-19 Covaxin vaccine to the U.S. market. vaccine manufacturer in india. agreement, Ocugen will have the commercial rights of the vaccine candidate in the U.S. and will be responsible for conducting clinical trials and obtaining emergency use authorization (U.S.) from the U.S. Food and Drug Administration.
In an indication of a step towards the Covaxin vaccine as a viable option to fight the pandemic and open new markets, the company has also asked permission from the governments of Bangladesh and Myanmar to conduct clinical trials.
Bharat Biotech, in India, obtained an emergency license from India’s General Drug Controller VG Somani for its fully inactivated SARS-COV2 vaccine despite having no efficacy data, after which it began the administration of vaccines on 16 January. The company has said it will come out with the first set of provisional Covaxin efficacy data from its ongoing phase 3 trials in two weeks.